|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/15/23 Nymox Pharmaceutical Corp. 6-K 9/30/23 45:2.1M Pubco Reporting … Inc/FA |
Document/Exhibit Description Pages Size
1: 6-K Current, Quarterly or Annual Report by a Foreign HTML 46K
Issuer
2: EX-99.1 Quarterly Report HTML 466K
3: EX-99.2 CEO HTML 20K
9: R1 Cover HTML 31K
10: R2 Consolidated Statements of Operations (Unaudited) HTML 54K
11: R3 Consolidated Statements of Financial Position HTML 63K
12: R4 Consolidated Statements of Financial Position HTML 16K
(Parenthetical)
13: R5 Consolidated Statements of Cash Flows (Unaudited) HTML 66K
14: R6 Consolidated Statements of Changes in Shareholders HTML 41K
Equity (Unaudited)
15: R7 Business Activities and Basis Of Presentation HTML 18K
16: R8 Going concern considerations HTML 17K
17: R9 Share capital HTML 61K
18: R10 Earnings per share HTML 28K
19: R11 Operating lease and other commitments HTML 35K
20: R12 Short term loan HTML 16K
21: R13 Commitments and Contingencies HTML 16K
22: R14 Related Party Transactions HTML 33K
23: R15 Subsequent events HTML 18K
24: R16 Business Activities and Basis Of Presentation HTML 20K
(Policies)
25: R17 Share capital (Tables) HTML 58K
26: R18 Earning Per Share (Tables) HTML 26K
27: R19 Operating leases and other commitment (Tables) HTML 33K
28: R20 Related Party Transactions (Tables) HTML 29K
29: R21 Share capital (Details) HTML 34K
30: R22 Share capital (Details 1) HTML 27K
31: R23 Share capital (Details 2) HTML 21K
32: R24 Share capital (Details Narrative) HTML 39K
33: R25 Earnings per share (Details) HTML 21K
34: R26 Operating lease and other commitments (Details) HTML 18K
35: R27 Operating lease and other commitments (Details 1) HTML 26K
36: R28 Operating lease and other commitments (Details HTML 20K
Narrative)
37: R29 Short term loan (Details Narrative) HTML 20K
38: R30 Related Party Transactions (Details) HTML 24K
39: R31 Related Party Transactions (Details Narrative) HTML 25K
40: R32 Subsequent events (Details Narrative) HTML 19K
43: XML IDEA XML File -- Filing Summary XML 75K
41: XML XBRL Instance -- nymox_6k_htm XML 520K
42: EXCEL IDEA Workbook of Financial Report Info XLSX 55K
6: EX-101.CAL XBRL Calculations -- nymox-20230930_cal XML 91K
8: EX-101.DEF XBRL Definitions -- nymox-20230930_def XML 149K
5: EX-101.LAB XBRL Labels -- nymox-20230930_lab XML 381K
7: EX-101.PRE XBRL Presentations -- nymox-20230930_pre XML 297K
4: EX-101.SCH XBRL Schema -- nymox-20230930 XSD 126K
44: JSON XBRL Instance as JSON Data -- MetaLinks 125± 167K
45: ZIP XBRL Zipped Folder -- 0001640334-23-002155-xbrl Zip 95K
FORM i 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the period ended i September 30, 2023
Commission File Number: i 001-12033
i Nymox Pharmaceutical Corporation |
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l): ☐
Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Exhibits |
| |
|
| |
| ||
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
NYMOX PHARMACEUTICAL CORPORATION |
| ||
(Registrant) | |||
| |||
By: | |||
| |||
| President and Chief Executive Officer | ||
Date: November 14, 2023
3 |
| This ‘6-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 11/15/23 | None on these Dates | ||
| Filed on: | 11/14/23 | |||
| For Period end: | 9/30/23 | |||
| List all Filings | ||||